Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole in Acute ABPA
NCT02440009Phase 3Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- May 2014
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of itraconazole in allergic bronchopulmonary aspergillosis (ABPA) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Relapse rates at 12 months and Glucocorticoid-dependent ABPA at 24 months. Started May 2014; status: completed.
02
Drugs
itraconazole
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT02440009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440009.